Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA.
Obes Rev. 2011 Dec;12(12):1050-62. doi: 10.1111/j.1467-789X.2011.00906.x. Epub 2011 Jul 19.
Clinicians are routinely challenged in their management of cancer patients because of the complexities of obesity and diabetes that are often found as comorbid conditions. Although attention has been given to optimizing treatment planning for these patients, less attention has been given to manage their obesity and diabetes. This suggests that newer, comprehensive approaches must be developed for the treatment of cancer patients as a 'whole' rather than as a single disease. While the specific pathologies of each are unique, years of research have indicated intimate molecular links between these chronic diseases. The contribution of sedentary lifestyles and poor dietary habits is recognized; however, the precise molecular links are still not well-explored. In addition, emerging evidence suggests the important role of microRNAs (miRNAs) in the development and progression of several diseases, yet their roles in linking obesity, diabetes and cancer are only now beginning to be recognized. It is hoped that miRNAs will serve as novel biomarkers and molecular targets for cancer therapy in patients with comorbid conditions. In this review, we discuss the current understanding of the pathobiology of obesity, diabetes and cancer, and document molecular roles of miRNAs linking cancer with obesity and diabetes.
临床医生在管理癌症患者时经常面临挑战，因为肥胖症和糖尿病的复杂性通常被视为合并症。尽管已经关注了优化这些患者的治疗计划，但对其肥胖症和糖尿病的管理关注较少。这表明，必须为癌症患者制定更新的、全面的治疗方法，将其作为一个“整体”而不是单一疾病进行治疗。虽然每种疾病的具体病理都具有独特性，但多年的研究表明这些慢性疾病之间存在密切的分子联系。久坐的生活方式和不良的饮食习惯的影响是公认的；然而，确切的分子联系仍未得到充分探索。此外，新出现的证据表明微小 RNA（miRNAs）在几种疾病的发生和发展中起着重要作用，但它们在将肥胖症、糖尿病和癌症联系起来的作用才刚刚开始被认识到。人们希望 miRNAs 能成为合并症癌症患者癌症治疗的新型生物标志物和分子靶标。在这篇综述中，我们讨论了肥胖症、糖尿病和癌症的病理生物学的当前理解，并记录了将癌症与肥胖症和糖尿病联系起来的 miRNAs 的分子作用。
